Table 2.
Variables | <6-cycle (N=29) | ≥6-cycle (N=29) | P-value |
---|---|---|---|
Sex | 1.000 | ||
Male | 26 | 26 | |
Female | 3 | 3 | |
Age | |||
>60 | 7 | 3 | 0.164 |
≤60 | 22 | 26 | |
Karnofsky performance status | 0.487 | ||
>80 | 23 | 25 | |
≤80 | 6 | 4 | |
T stage | 0.089 | ||
T1–2 | 6 | 12 | |
T3–4 | 23 | 17 | |
N stage | 0.487 | ||
N0–1 | 4 | 6 | |
N2–3 | 25 | 23 | |
Histology (WHO) | 1.000 | ||
Type I/II | 9 | 9 | |
Type III | 20 | 20 | |
Number of bone metastatic sites | 1.000 | ||
>3 | 16 | 16 | |
≤3 | 13 | 13 | |
Nasopharyngeal radiotherapy | 0.063 | ||
Yes | 13 | 20 | |
No | 16 | 9 |